(Q39267105)

English

The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Steven L Barriere

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Future Microbiology

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

281-289

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Hospital-acquired pneumonia. Attributable mortality and morbidity

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Pneumonia caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

In vitro activity of telavancin against resistant gram-positive bacteria

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

In vitro activity of TD-6424 against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies

1 reference

https://api.crossref.org/works/10.2217%2FFMB.14.4

21 January 2018

Identifiers

10.2217/FMB.14.4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39267105&oldid=1817364412"